ArticleEye (London, England)2026
Corneal confocal microscopy in fibromyalgia syndrome: small fiber neuropathy, and treatment outcomes.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess ocular surface symptoms, corneal sensitivity (CS), and corneal confocal microscopy (CCM) findings in fibromyalgia (FMS) patients compared to healthy controls and to investigate the effect of oral serotonin-noradrenaline reuptake inhibitor (SNRI) treatment on these parameters.
methodsNewly diagnosed FMS patients (42 eyes) and healthy controls (50 eyes) were included in this prospective controlled study. 5-Item Dry Eye Questionnaire (DEQ-5), esthesiometry, and CCM were performed. Subbasal nerve plexus was analysed with ACCMetrics, and corneal nerve fibre density (CNFD), branch density (CNBD), fibre length (CNFL), and fractal dimension (CNFrD) were obtained. Dendritic cell (DC) density was measured with ImageJ. Microneuromas were manually counted. Tortuosity was graded using Oliveira-Soto scale. FMS patients received SNRI treatment for 6th months. All measurements were repeated at 3rd and 6th months of treatment.
resultsDEQ-5 score was higher in FMS at all follow-ups (p < 0.0001), and decreased with treatment (p < 0.0001). CS in FMS was lower (p = 0.002), with no change following treatment (p = 0.202). CNFL, CNFD, CNBD, and CNFrD values were lower in FMS (p<0.05), and reached the control level at the 3rd month (p>0.05). Tortuosity, microneuromas, and mature DC (mDC) in FMS were higher than control at baseline (p < 0.05). Following treatment, tortuosity in FMS remained higher than in the control (p < 0.05), while mDC and microneuromas showed no significant difference between the groups (p > 0.05).
conclusionsOcular symptoms and corneal nerve pathologies were more common in FMS patients compared to healthy controls. Treatment of FMS with SNRIs provided promising outcomes by ameliorating symptoms and improving corneal nerve morphology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.